Abbott hopes its latest set of clinical trial diversity initiatives can address the most stubborn challenges that device companies and researchers face when trying to enroll diverse populations in clinical trials.
The underrepresentation of women and specific ethnic groups in US-based clinical trials has been well-documented for decades. About 40% of the US population is a member of an historically...